CA2476218A1 - Therapeutic compounds - Google Patents

Therapeutic compounds Download PDF

Info

Publication number
CA2476218A1
CA2476218A1 CA002476218A CA2476218A CA2476218A1 CA 2476218 A1 CA2476218 A1 CA 2476218A1 CA 002476218 A CA002476218 A CA 002476218A CA 2476218 A CA2476218 A CA 2476218A CA 2476218 A1 CA2476218 A1 CA 2476218A1
Authority
CA
Canada
Prior art keywords
ligand
linker
compound
transporter
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002476218A
Other languages
English (en)
French (fr)
Inventor
Peter C. Meltzer
Bertha K. Madras
Paul Blundell
Shanghao Lui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organix Inc
Harvard University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2476218A1 publication Critical patent/CA2476218A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA002476218A 2002-02-08 2003-02-10 Therapeutic compounds Abandoned CA2476218A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US35511102P 2002-02-08 2002-02-08
US60/355,111 2002-02-08
US36740002P 2002-03-25 2002-03-25
US60/367,400 2002-03-25
PCT/US2003/004023 WO2003066004A2 (en) 2002-02-08 2003-02-10 Therapeutic compounds

Publications (1)

Publication Number Publication Date
CA2476218A1 true CA2476218A1 (en) 2003-08-14

Family

ID=27737484

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002476218A Abandoned CA2476218A1 (en) 2002-02-08 2003-02-10 Therapeutic compounds

Country Status (6)

Country Link
US (2) US7439264B2 (cg-RX-API-DMAC10.html)
EP (1) EP1478356A4 (cg-RX-API-DMAC10.html)
JP (1) JP2005527495A (cg-RX-API-DMAC10.html)
AU (1) AU2003215150A1 (cg-RX-API-DMAC10.html)
CA (1) CA2476218A1 (cg-RX-API-DMAC10.html)
WO (1) WO2003066004A2 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100143248A1 (en) * 1999-06-28 2010-06-10 President And Fellows Of Harvard College Methods for diagnosing and monitoring treatment of adhd by assessing the dopamine transporter level
WO2001068104A1 (en) * 2000-03-16 2001-09-20 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
US7550485B2 (en) * 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
WO2005122767A1 (en) * 2004-06-10 2005-12-29 Mclean Hospital Corporation Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
EP1765364A4 (en) * 2004-06-10 2010-09-22 Mclean Hospital Corp PYRIMIDINES, SUCH AS Z: B: CYTIDINE, IN THE TREATMENT OF PATIENTS WITH BIPOLAR DISORDER
US7947661B2 (en) * 2004-08-11 2011-05-24 The Mclean Hospital Corporation Compounds for the treatment of marihuana dependence, withdrawal, and usage
US20060069086A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
WO2007100775A2 (en) * 2006-02-27 2007-09-07 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
GB2447949B (en) * 2007-03-29 2010-03-31 Renasci Consultancy Ltd A method for identifying a compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
US8697888B2 (en) * 2012-01-06 2014-04-15 Vanderbilt University Substituted (1-(methylsulfonyl)azetidin-3-yl)(heterocycloalkyl)methanone analogs as antagonists of muscarinic acetylcholine M1 receptors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531483B1 (en) 1990-08-09 2003-03-11 Research Triangle Institute Cocaine receptor binding ligands
US6241963B1 (en) 1995-10-19 2001-06-05 The Trustees Of The University Of Pennsylvania Dopamine and serotonin transporter ligands and imaging agents
US5948933A (en) 1997-07-11 1999-09-07 Organix, Inc. Tropane analogs and methods for inhibition of monoamine transport
AU1797700A (en) 1998-12-14 2000-07-03 Nuclear Receptor Research Limited Novel ligands of nuclear receptor
CA2721484A1 (en) 1999-05-12 2000-11-12 President And Fellows Of Harvard College Dopamine transporter imaging agents
US6479509B1 (en) 2000-05-22 2002-11-12 Research Triangle Institute Method of promoting smoking cessation
US6525206B1 (en) * 2000-10-17 2003-02-25 President And Fellows Of Harvard College Compounds with high monoamine transporter affinity
GB2380733A (en) 2001-10-11 2003-04-16 Bertha Kalifon Madras Non-amine tropane analogues

Also Published As

Publication number Publication date
US7439264B2 (en) 2008-10-21
US20030232827A1 (en) 2003-12-18
WO2003066004A2 (en) 2003-08-14
EP1478356A2 (en) 2004-11-24
EP1478356A4 (en) 2005-03-16
JP2005527495A (ja) 2005-09-15
AU2003215150A8 (en) 2003-09-02
AU2003215150A1 (en) 2003-09-02
US20090048284A1 (en) 2009-02-19
WO2003066004A3 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
US20090048284A1 (en) Therapeutic compounds
EP3416964B1 (en) 6-oxo-n-(1-(benzyl)-1h-pyrazol-4-yl)-6,7,8,9- tetrahydropyrido[3&#39;,2&#39;:4,5]pyrrolo[1,2-a]pyrazine-2-carboxamide derivatives as p90 ribosomal s6 kinase (rsk) inhibitors for treating cancer
ES2358673T3 (es) Antagonistas de receptores de acetilcolina muscarínicos.
ES2329739T3 (es) Analogos de cocaina.
US8987293B2 (en) Morphinans useful as analgesics
HRP20110946A2 (hr) Enantiomeri spirooksindolskih spojeva i njihova upotreba kao terapijska sredstva
Dutta et al. Dopamine transporter as target for drug development of cocaine dependence medications
US12630555B2 (en) Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists
US20030022901A1 (en) Serotonergic agents
JPH07503703A (ja) (−)−エゼロリン、(−)−n1−ノルエゼロリンおよび(−)−n1−ベンジルノルエゼロリンの置換フェンゼリンおよびフェニルカルバミン酸塩:特異的アセチルコリンエステラーゼ阻害薬としての使用
EP1358177B1 (en) Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
JP2001509508A (ja) トロパン類似物及びモノアミン輸送の抑制方法
US20230250098A1 (en) Kratom opioid derivatives for the treatment of alcohol use disorder
KR101960107B1 (ko) 통증의 치료를 위한 4,5에이-에폭시모르피난의 6-아미도 유도체
EP4460306A2 (en) Targeting swi/snf related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 (smarca4)
JP2010521500A (ja) 4−[2−(4−メチルフェニルスルファニル)フェニル]ピペリジン塩の液体製剤
WO2013062680A1 (en) Novel compounds and compositions thereof for treating nervous system disorders
KR100196263B1 (ko) 아로일 우레아 유도체
US11352365B2 (en) Biased potent opioid-like agonists as improved medications to treat chronic and acute pain and methods of using the same
KR20240088939A (ko) Dot1l 분해를 위한 소분자 및 이의 용도
US7816362B2 (en) Serotonergic agents
US20210061814A1 (en) G-protein biased opioid receptor agonist/analgesics with reduced arrestin recruitment
JP2001504850A (ja) 不安を伴う重抑鬱性障害を治療するためのnk−1受容体拮抗薬の使用
US20110251175A1 (en) Stigmine Conjugates for Substance Use Disorders
WO2026036128A1 (en) Compounds and methods for iron-dependent drug release

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued